Our Journey
We have seen and experienced firsthand the challenges faced by patients and cannulators during hemodialysis, inspiring us to embark on a mission to find a solution intended to be safe, simple, and effective. The Ark is the result of countless hours of hard work and dedication from the entire Voyager team to bring a revolutionary device that aims to standardize cannulation across multiple dialysis centers and home dialysis to benefit patients and medical providers across the world.
Alan Glowczwski, MD
Dr. Glow is the founder and Chief Medical Officer of Voyager Biomedical and the inventor of the Ark technology. He is a graduate of the McGovern Medical Center Diagnostic and an Interventional Radiologist with over twenty-five years of experience in the field. Before embarking on his Ark journey, Dr. Glow served as the Medical Director of Radiology at a private medical center. He also served as the Director of Imaging at Texas A&M Institute for Preclinical Studies. His inspiration to develop the Ark stems from his experiences as a diagnostic and interventional radiologist observing the complexities of vascular access in dialysis patients, motivating him to pursue a solution that will best facilitate and improve their vascular access.
Ashok Gowda, PhD
Dr. Ashok Gowda, Ph.D., is the Chief Executive Officer of Voyager Biomedical. He is also the founder and Chief Executive Officer of Biotex, a partner of the controlling entity for Voyager Biomedical. Dr. Gowda has over twenty-five years of experience in medical technology development, manufacturing, and commercialization. He is a previous founder of Visualase (acquired by Medtronic), an active angel investor, and a board member for multiple startups.
A Voyage of Discoveries
History
Originally a Senior Design Project with bioengineers from Texas A&M
Voyager Medical was nominated to participate in TMZX. Partnered with Biotex, Inc.
Chronic AVF Study Goat Models cannulating twice weekly
Received a 2.1M Grant from the National Institutes of Health (NIH)
GLP Goat Study for FDA
First in Human Study
Upcoming Milestones
Multi-Site US Study